An awareness of Voting initiated by Zen Multispeciality Hospital

IMT News Desk
IMT News Desk
· 2 min read

Making Responsible Choice by Voting

Voting is the fundamental right of the citizens of India. Voting will also enable citizens to realize the importance of citizenship. Many people do not vote, as they think one vote will not make a change, but as a matter of fact, it does. Making a responsible choice can help the country to grow by leaps and bounds, and bring a revolutionary change in the fields like healthcare, and it is vital for socio-economic development. Taking note of the upcoming Lok Sabha election, doctors, nurses and para-medical staff of Zen Multispeciality hospital has come up with a unique initiative.

The campaign by the hospital had begun with aims to create awareness regarding voting and appealing people to do their bit, step out and vote with an impactful message, “Vote for a healthy nation,” on the prescription notepad.  Appeal by doctors/ staff will help educate patients regarding their basic right. This awareness campaign carried out at the reception area of the hospital, as well as it will run on a digital platform through creative post/ video.

Dr Roy Patankar, Director of Zen Multispecialty says, “India is the largest democracy in the world. So, it is the responsibility of every Indian to come out, vote and help increase the voting percentage for the development of our country.  It is our primary right to choose the right government and leaders for our nation. Hence, like medication, voting is equally essential. Come let’s exercise our right, vote, and discharge our responsibilities towards the country. Get, set and vote!”

 

 

Read Next

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk
Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk